Year: 2019

RADNOR, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced today that Elan Ezickson, has joined the Company’s Board of Directors.  Mr. Ezickson is a highly accomplished executive with over 30 years of experience in the life sciences industry across commercial, operational and strategic leadership roles.“We are thrilled to welcome Elan to our board of directors,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus.  “His diverse leadership experience across the entire value chain of pharmaceutical operations, from capital raising to program development, will be invaluable to Marinus as we continue to execute...

VANCOUVER, British Columbia, Dec. 12, 2019 (GLOBE NEWSWIRE) — Serengeti Resources Inc. (SIR: TSX-V; 34S: FSE) announces a non-brokered Flow Through private placement financing to raise gross proceeds of up to CDN$1,500,000 through the sale of up to 6,250,000 flow-through common shares (“FT Shares”) at a price of $0.24 per FT Share (the “Offering”).The Offering is expected to close on or about December 17, 2019 (the “Closing Date”). Completion of the Offering is subject to receipt of all required regulatory and other approvals, including acceptance by the TSX Venture Exchange. All FT Shares issued pursuant to this private placement will be subject to a four month hold period from the Closing Date. The Offering is not subject to any minimum aggregate subscription.Incidental to the Offering, the Company has agreed to pay a 7% finders’...

WASHINGTON, D.C., Dec. 12, 2019 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the formal launch of its LIBOR Transition Task Force, a multidisciplinary group that leverages expertise from across the firm to help clients successfully navigate the transition from LIBOR to alternative reference rates before the 2021 deadline. FTI Consulting works with clients, industry groups, law firms, and policy makers to map out obstacles and the expertise required to navigate them. It also continues to monitor developments from industry working groups including ISDA, SFIG/SFA, LSFT, SIFMA, and ARRC.FTI Consulting’s LIBOR Transition Task Force is chaired by Executive Committee member John Klick and comprises senior experts from the firm’s core disciplines, including Franck Risler, William Nolan, Marc Walby, Colleen Hsia and...

KITCHENER, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) — James E. Wagner Cultivation Corporation (JWC) (TSX: JWCA.V; OTCQX: JWCAF), plans to open a 2,000 sf. farm-gate retail store adjoining its 340,000 sf. flagship cultivation facility located at 530 Manitou Drive in Kitchener, Ontario.As JWC scales toward full production capacity, it plans to expand from the Canadian medical to recreational markets in the first calendar quarter of 2020 through a number of marketing and distribution channels. The farm-gate store will represent a new direct-to-consumer outlet for the company, with its recently announced brokerage agreement with Kindred Partners providing a new sales channel for distribution through licensed third-party retailers.JWC Farm-gate is expected to be the Waterloo Region’s first retail cannabis store located on a licensed cultivation...

Licensed Producers and Multi-State Operators are recognizing the volumes of data they hold from production, retail, medical and product information but currently exist on disparate platforms across multiple geographies.Company completes full-scale platform development for a cloud-based data aggregation tool specializing in managing disparate data sources into a single platform to structure, clean and apply analytical models to address key health and product-related questions.The cloud-based system will improve efficiencies to clients needing to handle multiple, disparate systems for data collection, clinical trials or other research projects including supporting commercialization and new drug discovery.CB2 will work with existing partners to launch the platform in 2020 and will look to further commercialize across other verticals and...

Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in patients suffering from Bipolar I or Bipolar II disorder. Schizophrenia: Lumateperone’s clinical profile including its motor and cardiometabolic profile was showcased in pooled analyses of randomized short-term clinical trials and a long-term safety study.Lumateperone and the Metabolic Syndrome (MetSy): Post-hoc analyses from short-term placebo-controlled studies in schizophrenia on MetSy in patients treated with lumateperone and in patients treated with risperidone were presented.NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development...

F-Secure Corporation, Stock Exchange Release, 12 December 2019 at 14.40 EETF-Secure lowers its outlook for corporate security revenue growth in 2019 and guides clearly improving profitability for 2020Change in 2019 outlookF-Secure expects that revenue from corporate security will grow approximately 27-30% from previous year instead of over 30% as per previous guidance. Consumer security revenue and group EBITDA outlooks remain unchanged.Corporate security revenue growth is expected to be lower than anticipated due to the following factors:Utilization rates in cyber security consulting have been softer in some regions than expected during the last quarter of 2019.Significant multi-year deals in Managed Detection and Response (MDR) have been signed during the year in several main markets of the company. As the signing of some of these deals...

F-Secure Oyj, Pörssitiedote, 12.12.2019 klo 14.40F-Secure laskee arviotaan vuoden 2019 yritystietoturvan liikevaihdon kasvunäkymistä ja ohjeistaa selvästi paranevaa kannattavuutta vuodelle 2020Muutos 2019 näkymissäF-Secure arvioi, että yritystietoturvan liikevaihto kasvaa noin 27-30% edellisestä vuodesta aiemmin ohjeistetun yli 30% kasvuodotuksen sijaan. Kuluttajatietoturvan liikevaihdon ja tilikauden käyttökateohjeistuksen osalta näkymät säilyvät ennallaan.Yritystietoturvan liikevaihdon kasvun ennakoidaan jäävän odotettua matalammaksi seuraavista syistä johtuen:Kyberturvallisuuskonsultoinnin käyttöasteet ovat olleet joillakin alueilla odotettua alhaisemmat vuoden 2019 viimeisellä vuosineljänneksellä.Vuoden aikana on voitettu merkittäviä monivuotisia sopimuksia MDR-liiketoiminnassa (Managed Detection and Response) useilla yhtiön päämarkkinoilla....

2019-12-12Kvalitena emitterar ytterligare obligationer om 100 MSEKKvalitena AB (publ) (”Kvalitena” eller ”Bolaget”) meddelar härmed att Bolaget framgångsrikt har emitterat ytterligare obligationer om 100 MSEK inom ramen för Kvalitenas existerande upp till 800 MSEK icke säkerställda obligationsram med ISIN SE0012675155 och slutförfall i december 2022. De ytterligare obligationerna emitterades till ett pris om 100,00 procent av det nominella beloppet. Total utestående volym uppgår efter emissionen till 800 MSEK.I samband med emissionen har Kvalitena köpt tillbaka obligationer om 10 MSEK i förfallet 2020. Övrig del av emissionslikviden ska användas för generella verksamhetsändamål. De befintliga obligationerna är noterade på Nasdaq Stockholm och Kvalitena kommer att ansöka om att även de nyemitterade obligationerna tas upp till handel...

Í 50. viku 2019 hefur Reitir fasteignafélag hf. nú keypt 1.000.000 eigin hluti fyrir 73.860.000 kr. eins og hér segir:Endurkaupaáætlun Reita fasteignafélags hf., sem tilkynnt var um í Kauphöll þann 1. september 2019, er nú lokið og hefur áætlun félagsins um kaup á eigin bréfum verið náð.Samkvæmt áætluninni máttu endurkaup félagsins nema allt að 20.000.000 hlutum og heildarkaupverð mátti ekki nema hærri fjárhæð en 1.500 milljónum króna. Endurkaupaáætlunin var í gildi til 31. janúar 2020 nema öðru hvoru framangreindra marka yrði náð áður. Félagið hefur nú keypt samtals 20.000.000 hluti fyrir samtals 1.475.865.000 kr. og er því framangreindu marki um fjölda keyptra hluta náð. Reitir eiga nú samtals sem nemur 2,90% af heildarhlutafé félagsins.Endurkaupaáætlunin var framkvæmd í samræmi við ákvæði hlutafélagalaga nr. 2/1995 og viðauka við reglugerð...